Gossamer Bio (NASDAQ:GOSS) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Gossamer Bio (NASDAQ:GOSS) from a hold rating to a sell rating in a research note issued to investors on Sunday morning,Wall Street Zen reports.

GOSS has been the subject of a number of other reports. Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price target for the company in a research note on Tuesday, July 28th. Weiss Ratings upgraded shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Gossamer Bio in a report on Thursday, August 27th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $256.00.

Gossamer Bio Price Performance

GOSS stock opened at $11.69 on Friday. Gossamer Bio has a 1 year low of $9.10 and a 1 year high of $309.60. The company has a market cap of $34.30 million, a P/E ratio of -0.21 and a beta of 2.00. The stock’s fifty day moving average price is $13.12 and its 200-day moving average price is $19.95.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in GOSS. Hsbc Holdings PLC increased its stake in shares of Gossamer Bio by 1,289.4% in the second quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock worth $267,000 after purchasing an additional 1,469,175 shares in the last quarter. Corient Private Wealth LP bought a new stake in shares of Gossamer Bio during the 2nd quarter valued at $926,000. Kalehua Capital Management LLC purchased a new position in shares of Gossamer Bio during the 1st quarter valued at $3,363,000. Hhlr Advisors LTD. purchased a new position in shares of Gossamer Bio during the 2nd quarter valued at $819,000. Finally, GSA Capital Partners LLP bought a new position in Gossamer Bio in the 2nd quarter worth $2,467,000. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for pulmonary and inflammatory diseases. The company’s research is centered on therapeutic areas with significant unmet medical needs, including pulmonary hypertension and other immune-mediated conditions.

Gossamer Bio’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary arterial hypertension and pulmonary vascular remodeling.